Skip to main content

Defiance Junior Biotech ETF (IBBJ)

NASDAQ: IBBJ · IEX Real-Time Price · USD
28.22 -0.25 (-0.86%)
Oct 22, 2021 4:00 PM EDT - Market closed
Expense Ratio0.45%
PE Ration/a
Shares Out250,000
Dividend (ttm)$0.30
Dividend Yield1.05%
Ex-Dividend DateDec 29, 2020
1-Year Return
Previous Close28.47
Day's Range28.05 - 28.55
52-Week Low26.78
52-Week High41.45
Inception DateAug 3, 2020

About IBBJ

The investment seeks to track the total return performance, before fees and expenses, of the NASDAQ Junior Biotechnology Index. The index is a rules-based index that consists of a portfolio of the stock of U.S.-listed small capitalization (junior) companies screened from the universe of the NASDAQ Biotechnology Index. The fund will generally use a replication strategy to achieve its investment objective, meaning it will generally invest in all of the component securities of the index in the same approximate proportions as in the index. The fund is non-diversified.

Asset ClassEquity
IssuerDefiance ETFs
Stock ExchangeNASDAQ
Ticker SymbolIBBJ
Index TrackedNasdaq Junior Biotechnology Index

Top 10 Holdings

20.86% of assets
Intellia TherapeuticsNTLA3.07%
Zai LabZLAB2.24%
BridgeBio PharmaBBIO2.20%
Medpace HoldingsMEDP2.18%
Beam TherapeuticsBEAM2.03%
Twist BioscienceTWST1.88%
Kodiak SciencesKOD1.88%
Fate TherapeuticsFATE1.84%
Halozyme TherapeuticsHALO1.76%
View More Holdings


Ex-DividendAmountPay Date
Sep 22, 2021$0.000Sep 24, 2021
Jun 23, 2021$0.000Jun 25, 2021
Mar 24, 2021$0.000Mar 26, 2021
Dec 29, 2020$0.29981Dec 31, 2020
Full Dividend History


Biotech ETFs Benefit From Moderna Dual Booster Shot News

As the stock market attempts to reverse the recent pullback this month, Moderna shares climbed higher on Thursday after the company announced that it's creating a dual-purpose vaccine booster shot that ...

Other symbols:MRNAPBE
1 month ago - ETF Trends

Could Biotech ETFs Get Another Boost From JNJ News?

This has been a pivotal week for biotech news, as Johnson & Johnson said Wednesday that a booster shot of its COVID-19 vaccine generated a promising immune response in early stage clinical trials. This ...

Other symbols:BIBPBE
1 month ago - ETF Trends

When Will Smaller Biotech Firms Get Their Big Break?

Smaller biotechnology stocks aren't setting the world on fire this year, but some analysts believe it's a matter of when, not if, that situation reverses. Should small biotechnology names get their resp...

1 month ago - ETF Trends

Healthcare ETFs Surge on FDA Full-Vaccine Nod & Deal News

The FDA granted full approval of a COVID-19 vaccine made by Pfizer (PFE) and BioNTech that could accelerate inoculations in the United States.

2 months ago - Zacks Investment Research

Biotech ETFs Are Already Benefitting from Pfizer Vaccine's Full Approval

There could be big gains ahead for biotech ETFs, as the Food and Drug Administration on Monday fully approved the Pfizer and BioNTech coronavirus vaccine, making it the first vaccine in the U.S. to be a...

Other symbols:BIBPBE
2 months ago - ETF Trends

Bet on Biotech Small Caps to Bounce Back

Large cap biotechnology have strengthened in recent months, but smaller counterparts are still waiting on their 2021 moment. When that happens, the Defiance Nasdaq Junior Biotechnology ETF (IBBJ) could ...

2 months ago - ETF Trends

7 Stocks to Buy Now if You're Feeling Greedy While Others Are Fearful

Stock markets run on fear and greed in the short term. Here are seven stocks to buy that look like they have significant long-term upside.

4 months ago - InvestorPlace

Why Small Cap Biotech ETFs Are Still Brilliant Bets

Small cap stocks are retreating. So are biotechnology names.

6 months ago - ETF Trends

Consider Smaller Biotech ETFs as Big Pharma Goes Shopping in 2021

After a lull in mergers and acquisitions activity, Big Pharma could begin to use its cash stores to buy out smaller targets, potentially fueling the momentum in biotechnology-related exchange traded fun...

Other symbols:SBIOXBI
9 months ago - ETF Trends

New Biotech ETF Quick To Strut Its Stuff

There are recipes for success for new exchange-traded funds. In an effort to attract assets and investors' attention, rookie ETFs can undercut established rivals on fees, offer exposure to a compelling ...

11 months ago - Benzinga

Young But Hungry: A New Defiance ETF is Defying Expectations

The Defiance Nasdaq Junior Biotechnology ETF (IBBJ) is just a few months in, but it's already asserting itself in the biotechnology exchange traded funds arena, one teeming with competition. IBBJ tracks...

11 months ago - ETF Trends

IBBJ ETF, the Junior Biotech ETF Outperforming Nasdaq Biotechnology Index

NEW YORK--(BUSINESS WIRE)---- $IBBJ #Biotech--About Defiance: Founded in 2018, Defiance ETFs is an exchange-traded funds (ETFs) sponsor and registered investment advisor, focused on thematic investing. ...

11 months ago - Business Wire

"Worst September in 18 Years"? 4 Sector ETFs Surviving Selloffs

After a superb August, September looks gloomy for Wall Street. Still,

1 year ago - Zacks Investment Research

Healthcare ETFs, Stocks That Gained Double Digits Last Week

The healthcare sector defied last week's market rout buoyed by the progress in the development of a coronavirus vaccine or treatment, and merger and acquisition news.

1 year ago - Zacks Investment Research

4 Best-Performing Sector ETFs of Last Week

The S&P 500, the Dow Jones and the Nasdaq Composite have lost about 0.6%, 0.03% and 0.6%, respectively, past week.

Other symbols:BTECBETZLIT
1 year ago - Zacks Investment Research

3 ETFs To Play Gilead's $21B Immunomedics Takeover

Biotechnology mergers and acquisitions appear to be back in a big way with news that Gilead Sciences (NASDAQ: GILD) is acquiring Immunomedics (NASDAQ: IMMU) for $21 billion.

Other symbols:BTECPTH
1 year ago - Benzinga

Small-Cap Biotechnology ETF Brings Big Opportunity

The Defiance Nasdaq Junior Biotechnology ETF (IBBJ) is still in its infancy in the biotechnology ETFs arena, having debuted just last month, but a big opportunity comes with this rookie ETF. IBBJ tracks...

1 year ago - ETF Trends

This Baby Biotech ETF Has Big Potential

The Defiance Nasdaq Junior Biotechnology ETF (NYSE: IBBJ) is the newest addition to the biotechnology exchange traded funds fray, having debuted about a month ago.

1 year ago - Benzinga

Why Small-Cap Biotech ETFs Are Good Long-Term Bets

Small-cap biotech ETFs may prove to be winning bets with or without coronavirus.

Other symbols:BBCBTECIDNA
1 year ago - Zacks Investment Research

ETF of the Week: Defiance Nasdaq Junior Biotechnology ETF (IBBJ)

ETF Trends CEO Tom Lydon discussed the Defiance Nasdaq Junior Biotechnology ETF (IBBJ) on this week’s “ETF of the Week” podcast with Chuck Jaffe on the MoneyLife Show. IBBJ covers companies around the g...

1 year ago - ETF Trends

A Junior Biotech ETF With Home Run Potential

The Defiance Nasdaq Junior Biotechnology ETF (IBBJ) is one of the newest exchange traded funds on the market and it could be one of the most appropriate for the current environment. IBBJ’s 176 member fi...

1 year ago - ETF Trends

New Biotech ETF Taps Into Small But Mighty Theme

Extending what’s been a busy stretch of unique healthcare ETF launches, the Defiance Nasdaq Junior Biotechnology ETF (IBBJ) debuted on Tuesday, coming to market at a time when biotechnology ETFs, broadl...

1 year ago - ETF Trends

Hey, Junior: New Biotech ETF Goes Small In Search Of Big Winners

With significant help from the fight against the coronavirus, biotechnology stock and exchange-traded funds are setting torrid paces this year.

1 year ago - Benzinga

Junior Biotech ETF Debuts

New fund invests in small-cap biotechnology stocks. 

Other symbols:IBBXBI
1 year ago - ETFcom

Defiance Debuts Nasdaq Junior Biotechnology ETF (IBBJ)

Defiance ETFs debuted a new ETF today with targeted exposure to the junior disruptors in the biotech space.

1 year ago - ETF Trends